The Technical Analyst
Allarity Therapeutics, [ALLR]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Allarity Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.01% $1.370
America/New_York / 25 apr 2024 @ 12:26
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.646 mill |
| EPS: | -205.20 |
| P/E: | -0.0100 |
| Earnings Date: | May 24, 2024 |
| SharesOutstanding: | 0.471 mill |
| Avg Daily Volume: | 0.520 mill |
| RATING 2024-04-25 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0100 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.0100 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.630 - 2.11 ( +/- 54.01%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-08-01 | Benjamin Laura | Buy | 0 | |
| 2023-08-01 | Vazzano Joseph Walter | Buy | 0 | |
| 2021-12-20 | Carchedi Steve | Sell | 70 477 | Stock Options |
| 2021-12-20 | Carchedi Steve | Sell | 156 025 | Stock Options |
| 2021-12-20 | Carchedi Steve | Sell | 252 555 | Stock Options |
| INSIDER POWER |
|---|
| 0.00 |
| Last 5 transactions |
| Buy: 0 | Sell: 505 299 |
Forecast:
14:05 - $1.360
Live Trading Signals (every 1 min)
Forecast
1: 12:35 - $1.371
Forecast 2: 13:25 - $1.375
Forecast 3: 14:05 - $1.360
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.370 (0.01% ) |
| Volume | 0.0612 mill |
| Avg. Vol. | 0.520 mill |
| % of Avg. Vol | 11.79 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ALLR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ALLR
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2024-04-17 09:10:00 - Press Release
Allarity Therapeutics Receives Nasdaq-approved Extension To Regain Compliance With Nasdaq Listing Rule 5550(b)(1)
Boston (april 17, 2024)—allarity therapeutics, inc. (“allarity” or the “company”) (nasdaq: allr), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that it had been granted an extension until may 14, 2024, to regain compliance with nasdaq listing rule 5550(b)(1).
2024-04-04 09:15:00 - Press Release
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
Boston (april 4, 2024) — allarity therapeutics, inc. (“allarity” or the “company”) (nasdaq: allr), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced the implementation of a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20 (the “reverse stock split”). the reverse stock split will become effective at 9:30 a.m. eastern time on april 9, 2024. the company's common stock will begin trading on a split-adjusted basis when the market opens on april 9, 2024. this strategic move aims to regain compliance with the nasdaq's minimum bid price requirement, alongside achieving other operational benefits...
2024-03-27 08:30:00 - Press Release
Allarity Therapeutics Makes Strategic Pivot To Focus Solely On Accelerating Stenoparib Toward Regulatory Approval In Advanced Recurrent Ovarian Cancer
The stenoparib phase 2 monotherapy trial in advanced, recurrent ovarian cancer continues to show promise, prompting shift in resources to accelerate stenoparib development further development of ixempra ® and dovitinib is de-prioritized the company has been able to reduce costs materially boston (march 27, 2024) — allarity therapeutics, inc. (“allarity” or the “company”) (nasdaq: allr), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced a strategic pivot aimed at advancing its clinical-stage candidate stenoparib, a novel parp/tankyrase dual inhibitor, toward registration in advanced recurrent ovarian cancer, leveraging its drp® platform to identify and enroll only the patients most likely to derive clinical benefit...
2024-03-25 07:30:00 - Press Release
Allarity Therapeutics Receives Extension From Nasdaq Hearings Panel To Regain Compliance With Listing Rules 5550(a)(2) And 5550(b)(1)
Boston (march 25, 2024) — allarity therapeutics, inc. (“allarity” or the “company”) (nasdaq: allr), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that the company has been granted a formal extension until april 24, 2024 to regain compliance under nasdaq listing rules 5550(a)(2) (the “bid price rule”) and 5550(b)(1) (the “equity rule”) or any of the alternative requirements in listing rule 5550(b).
2024-03-08 07:15:00 - Press Release
Allarity Therapeutics Reports Full Year 2023 Financial Results And Provides A Business Update
Boston (march 8, 2024) — allarity therapeutics, inc. (“company”) (nasdaq: allr), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today reported financial results for the year ended december 31, 2023, and provided a general business update.
Latest News
2024-04-12 08:18:18 - InvestorPlace
Why Is Allarity Therapeutics (ALLR) Stock Up 41% Today?
Allarity Therapeutics (NASDAQ: ALLR ) stock is heading higher on Friday alongside heavy pre-market trading. Investors will note that this movement comes after the company announced a prospectus supplement.
2024-02-28 06:00:00 - GlobeNewsWire
Allarity Therapeutics to Present at Biomarkers 2024
Boston (February 28, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, is pleased to announce that it has been invited to present at Biomarkers 2024.
2023-12-05 10:07:43 - InvestorPlace
Why Is Allarity Therapeutics (ALLR) Stock Up 42% Today?
Allarity Therapeutics (NASDAQ: ALLR ) stock is taking off on Tuesday after the clinical-stage biopharmaceutical company released data from a Phase 2 clinical trial of stenoparib. That clinical trial saw the company testing the effectiveness of stenoparib in women with advanced ovarian cancer.
2023-10-02 07:00:00 - GlobeNewsWire
Allarity Therapeutics to Present at Biomarkers Europe 2023
BOSTON , October 2, 2023 — Allarity Therapeutics, Inc. (Allarity or the Company) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, is pleased to announce that the Company has been invited to give a presentation at Biomarkers Europe 2023. The presentation will focus on Allarity's development of drug-specific DRP® companion diagnostics (CDx) for oncology therapeutics, featuring clinical validation for several exemplary DRP® CDx.
2023-08-04 07:52:43 - Benzinga
Top 5 Health Care Stocks That Could Blast Off In August - Biolase (NASDAQ:BIOL), Allarity Therapeutics (NASDAQ:ALLR)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
2023-07-05 14:12:16 - InvestorPlace
Why Is Allarity Therapeutics (ALLR) Stock Up 30% Today?
Shares of clinical-stage precision medicine company Allarity Therapeutics (NASDAQ: ALLR ) initially soared to a 60% gain for the midweek session before paring down gains to roughly 30%. Undergirding sentiment was early-stage data evaluating the efficacy of Ixempra — a metastatic breast cancer therapeutic — at multiple sites in Europe.
2023-04-19 08:36:15 - InvestorPlace
Why Is Allarity Therapeutics (ALLR) Stock Down 22% Today?
Allarity Therapeutics (NASDAQ: ALLR ) stock is falling hard on Wednesday after the clinical-stage pharmaceutical company launched a public offering. That public offering has the company selling up to $20 million in shares, as well as warrants to purchase its stock.
2023-04-16 06:30:42 - InvestorPlace
7 Sorry Pharma Stocks to Sell in April Before It's Too Late
Finding the best pharma stocks to sell can be an all-or-nothing kind of business. If you score on a company making a breakthrough in a new drug or treatment, the rewards can be extreme, but investing in pharma stocks can also mean heavy expenditures on research and testing for a drug that may not perform as well as scientists hope.
2023-03-28 08:34:00 - Market Watch
Allarity's stock falls after saying enrollment in two clinical trials is slow
Shares of Allarity Therapeutics Inc. ALLR, -4.51% plunged 17% in premarket trading on Tuesday after the company told investors that it's struggled to enroll enough patients in Phase 2 studies for Ixempra and senoparib, citing the impact of the pandemic on staffing for clinical-trial sites. The company is testing Ixempra as a treatment for metastatic breast cancer and stenoparib for ovarian cancer.
2023-03-25 10:00:54 - Pulse2
Allarity Therapeutics: 1:35 Reverse Stock Split Goes Into Effect
Allarity Therapeutics announced that it intends to effect a reverse stock split of its common stock, at a ratio of 1 post-split share for every 35 pre-split shares. The post Allarity Therapeutics: 1:35 Reverse Stock Split Goes Into Effect appeared first on Pulse 2.0.